These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 28846180)
1. Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells. Kutkowska J; Strzadala L; Rapak A Cancer Sci; 2017 Nov; 108(11):2265-2272. PubMed ID: 28846180 [TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia increases the apoptotic response to betulinic acid and betulin in human non-small cell lung cancer cells. Kutkowska J; Strzadala L; Rapak A Chem Biol Interact; 2021 Jan; 333():109320. PubMed ID: 33181113 [TBL] [Abstract][Full Text] [Related]
4. Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells. Kutkowska J; Strzadala L; Rapak A Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347681 [TBL] [Abstract][Full Text] [Related]
5. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. Paz-Ares L; Hirsh V; Zhang L; de Marinis F; Yang JC; Wakelee HA; Seto T; Wu YL; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong TJ; Peña C; Smit EF; Mok TS J Thorac Oncol; 2015 Dec; 10(12):1745-53. PubMed ID: 26743856 [TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Pasqualetti G; Ricciardi S; Mey V; Del Tacca M; Danesi R Lung Cancer; 2011 Nov; 74(2):197-205. PubMed ID: 21529991 [TBL] [Abstract][Full Text] [Related]
7. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis. Chen C; Ju R; Shi J; Chen W; Sun F; Zhu L; Li J; Zhang D; Ye C; Guo L J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157 [TBL] [Abstract][Full Text] [Related]
8. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Caiola E; Frapolli R; Tomanelli M; Valerio R; Iezzi A; Garassino MC; Broggini M; Marabese M Sci Rep; 2018 Jan; 8(1):948. PubMed ID: 29343688 [TBL] [Abstract][Full Text] [Related]
9. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Groenendijk FH; Mellema WW; van der Burg E; Schut E; Hauptmann M; Horlings HM; Willems SM; van den Heuvel MM; Jonkers J; Smit EF; Bernards R Int J Cancer; 2015 Mar; 136(6):1434-44. PubMed ID: 25080865 [TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lim SM; Cho BC; Kim SW; Kang SY; Heo DS; Kim HT; Lee DH; Kim DW; Jung M; Choi JH; Shim HS; Choi JR; Kim JH Lung Cancer; 2016 Mar; 93():1-8. PubMed ID: 26898607 [TBL] [Abstract][Full Text] [Related]
13. Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Ko JL; Lin CH; Chen HC; Hung WH; Chien PJ; Chang HY; Wang BY Environ Toxicol; 2018 Nov; 33(11):1153-1159. PubMed ID: 30136359 [TBL] [Abstract][Full Text] [Related]
14. Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status. Dolgikh N; Fulda S Anticancer Drugs; 2017 Nov; 28(10):1118-1125. PubMed ID: 29045271 [TBL] [Abstract][Full Text] [Related]
15. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells. Li J; Chen Y; Wan J; Liu X; Yu C; Li W Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452 [TBL] [Abstract][Full Text] [Related]
16. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis. Yan WY; Cai J; Wang JN; Gong YS; Ding XB Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996 [TBL] [Abstract][Full Text] [Related]
17. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo. Zhang H; Li Z; Wang K Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815 [TBL] [Abstract][Full Text] [Related]
18. [Betulinic acid inhibits non-small cell lung cancer by repolarizing tumor-associated macrophages via mTOR signaling pathway]. Zeng AQ; Chen X; Dai Y; Zhao JN Zhongguo Zhong Yao Za Zhi; 2024 May; 49(9):2376-2384. PubMed ID: 38812138 [TBL] [Abstract][Full Text] [Related]
19. Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines. He X; Zhang T Cell Biochem Biophys; 2014 Mar; 68(2):411-8. PubMed ID: 23990130 [TBL] [Abstract][Full Text] [Related]
20. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]